Our Science

SL-325 chromosome
SL-325

Scientists in lab reviewing results

Two scientists in lab reviewing test from a machine

From our scientific expertise in protein engineering, we have advanced SL-325, a first-in-class DR3 antagonist. Our preclinical studies demonstrate high affinity binding, superior efficacy over TLIA antibodies, and offer a data-driven rationalization for targeting the TNF receptor, DR3, versus its ligand, TLIA.

  • Efficiently blocks soluble trimeric and membrane bound TL1A binding to DR3
  • pM binding affinity to DR3
  • Highly selective and does not cross-bind to other members of the TNF receptor family and the decoy receptor 3 (DcR3)
  • Fully Fc-silenced to prevent unwanted immune activation

Citations:

  1. Bamias G, et al. Gut 2024.
  2. Schreiber T, et al. Immunol Res 2013

ct sl here 5: